Alongside developing vaccines, scientists at the German Center for Infection Research (DZIF) are working at high speed to develop new drugs to improve the treatment of COVID-19 patients. A DZIF
In the global fight against the new coronavirus, an increasing number of clinical trials are being conducted on drugs to fight the virus in many countries of the world including Germany. In order to
A top global priority is to find agents that can stop the severe course of COVID-19 infection and consequently increase the chances of patient survival as rapidly as possible. Specific tests have
A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings
The European Research Council (ERC) awarded Prof Marcus Altfeld, Heinrich-Pette-Institute (HPI) and University Medical Center Hamburg-Eppendorf (UKE), an ERC Advanced Grant. This highly endowed grant
Research has been called to develop drugs, vaccines and testing methods as quickly as possible to fight the SARS-coronavirus-2. A fast-track procedure has made additional funding available to
The reserve antibiotic daptomycin is used primarily when conventional drugs fail due to resistant bacteria. Although the antibiotic was developed around 30 years ago, its exact mode of action was
The new coronavirusSARS-CoV-2 has been identified as the pathogen behind the COVID-19 pandemic. The virus contains a main protease termed Mpro (or also termed 3CLpro), which is involved in the
When do patients infected with the new coronavirus develop severe symptoms and when do they develop mild courses of disease? What is the best possible treatment and which measures have been successful
Scientists and physicians at the German Center for Infection Research (DZIF) have been closely monitoring and investigating the development of the novel coronavirusSARS-CoV-2 since it first emerged
